

COPY OF RATHERS
ORIGINALLY FILED

1614

Please type or sign in this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

6

Application Number

09/836,073

Filing Date

April 16, 2001

First Named Inventor

Asim DASGUPTA

Group Art Unit

1814

Examiner Name

To Be Assigned

RECEIVED
TECH CENTER 1600 APR 05 2002
TECH CENTER 1600 APR 05 2002

Attorney Docket No. 220002054822

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement; PTO form 1449	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

APR 03 2002


RECEIVED
TECH CENTER 1600 APR 03 2002

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


Firm or Individual Name	Kate H. Murashige Registration No. 29,959
Signature	
Date	January 11, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on January 11, 2002.


Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

1614 #7
MWPATENT FILED
Docket No. 220002054892

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on January 16, 2002.

Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Asim DASGUPTA et al.

Serial No.: 09/836,073

Filing Date: April 16, 2001

For: METHODS TO INHIBIT VIRAL
REPLICATION

Examiner: To Be Assigned

Group Art Unit: 1614

RECEIVED
APR 03 2002
TECH CENTER 1600/2900
FEB 05 2002
TECH CENTER 1600/2900INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/316,630, filed May 21, 1999, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of * is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 220002054822. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 11, 2002

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 220002054822	Application Number 09/836,073
		Applicant	Asim DASGUPTA et al.
		Filing Date April 16, 2001	Group Art Unit 161
		Mailing Date January 11, 2002	



RECEIVED
FEB 05 2002
TECH CENTER 1600
USPTO

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	04/1996	WO 96/11211	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Agol, Adv. Virus Res. (1991) 40:103-180
	3.	Agrawal, TIBTACH Vol. 14:376-387
	4.	Bandopadhyay et al., J. Virol. (1992) 66:6249-6256
	5.	Belsham et al., J. Virol. (1990) 64:5389-5395
	6.	Borman et al., Gen. Virol. (1993) 74:1775-1788
	7.	Borman et al., Virology (1992) 188:685-696
	8.	Borovjagin et al., Nucleic Acids Res. (1991) 19:4999-5005
	9.	Brown et al., Virology (1979) 97:376-405
	10.	Chambers et al., Journal of Biological Chemistry (1988) 263(34):18043-18061
	11.	Chang et al., J. Virol. (1993) 67:6716-6725
	12.	Chang et al., J. Virol. (1994) 68(11):7008-7020
	13.	Coward et al., J. Cell. Biochem. (1991) Suppl. 15E, abstract M311, p.82
	14.	Coward et al., J. Virol. (1992) 66:286-295
	15.	Das et al., J. Virol. (1994) 68(11):7200-7211
	16.	del Angel et al., Proc. Natl. Acad. Sci. USA (1989) 86:8299-8303
	17.	Dorner et al., J. Virol. (1984) 50:507-514

RECEIVED
APR 03 2002
TECH CENTER 1600
USPTO

EXAMINER: (examiner)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FEB 01 2002

Form PTO-1449
INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002054822	Application Number 09/836,073
Applicant	Asim DASGUPTA et al.
Filing Date April 16, 2001	Group Art Unit 1614
Mailing Date January 11, 2002	

18.	Gebhard et al., J. Virol. (1992) 66:3101-3109
19.	Glass et al., Virology (1993) 193:842-852
20.	Hellen et al., Proc. Natl. Acad. Sci. USA (1993) 90:7642-7646
21.	International Search Report based on International Application No. PCT/US99/11281
22.	Jackson et al., Trends Biochem. Sci. (1990) 15:477-483
23.	Jang et al., Genes Dev. (1990) 4:1560-1572
24.	Kitamura et al., Nature (1981) 291:547-553
25.	Kohara et al., J. Virol. (1992) 66:1476-1483
26.	Kozak, Microbiol. Rev. (1983) 47:1-45
27.	Luz et al., FEBS Letters (1990) 269:311-314
28.	Luz et al., Virology (1991) 65:6486-6494
29.	Macejak et al., Nature (1991) 353:90-94
30.	Meerovitch et al., Genes Dev. (1989) 3:1026-1034
31.	Meerovitch et al., J. Virol. (1993) 67:3798-3807
32.	Najita, Proc. Natl. Acad. Sci. USA (1990) 87:5846-5850
33.	Oh et al., Genes Dev. (1992) 6:1643-1653
34.	Pelletier et al., J. Virol. (1988) 62:4486-4492
35.	Pelletier et al., Nature (1988) 334:320-325
36.	Pestova et al., J. Virol. (1991) 65:6194-6204
37.	Pilipenko et al., Cell (1992) 68:119-131
38.	Racaniello et al., Proc. Natl. Acad. Sci. USA (1981) 78:4887-4891
39.	Skinner et al., J. Mol. Biol. (1989) 207:379-392
40.	Stull et al., Pharmaceutical Research 12(4):465-483

RECEIVED
TECH CENTER 1600/2900
APR 03 2004RECEIVED
TECH CENTER 1600/2900
APR 03 2004

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE